Latest Nilotinib Stories
A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib.
New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse.
Although significant progress has been made in treating chronic myeloid leukemia, the disease cannot yet be eliminated in all patients, and that challenge must be addressed.
SUNNYVALE, Calif., Aug. 9, 2011 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated XpertÂ® BCR-ABL Monitor test, now reporting results to the International Scale.
Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib.
FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for chronic myeloid leukemia (CML) patients.
EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Speaking at the UK National Stem Cell Network conference in York later today (31 March), Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia (CML) in which a small number of cancer cells persist despite effective therapy thus preventing cure.